Rosenberg J C, Sell T L
Arch Surg. 1975 Aug;110(8):980-3. doi: 10.1001/archsurg.1975.01360140124024.
In order to determine which drugs would be most effective as inhibitors of platelet release and aggregation, in vitro release reactions and platelet aggregometry were used to evaluate aspirin, dipyridamole, sulfinpyrazone, flurbiprofen, low molecular weight dextran (dextran 40), prostaglandin E1 (PGE1), apyrase, and adenosine. Adenosine diphosphate-induced aggregation was most effectively inhibited by PGF1, sulfinpyrazone, and dipyridamole. The latter had to be used in large doses. Collagen and epinephrine-induced release and aggregation were inhibited by the same drugs as well as by aspirin and apyrase. Antihynocyte globulin (ATG)-induced release and aggregation could only be partially blocked by these agents. In vitro studies suggest that sulfinpyrazone is one of the most effective of platelet inhibitors currently available for clinical testing.
为了确定哪些药物作为血小板释放和聚集抑制剂最为有效,采用体外释放反应和血小板聚集测定法对阿司匹林、双嘧达莫、磺吡酮、氟比洛芬、低分子量右旋糖酐(右旋糖酐40)、前列腺素E1(PGE1)、腺苷三磷酸双磷酸酶和腺苷进行评估。二磷酸腺苷诱导的聚集最有效地被PGF1、磺吡酮和双嘧达莫抑制。后者必须大剂量使用。胶原和肾上腺素诱导的释放和聚集被上述相同药物以及阿司匹林和腺苷三磷酸双磷酸酶抑制。抗人淋巴细胞球蛋白(ATG)诱导的释放和聚集只能被这些药物部分阻断。体外研究表明,磺吡酮是目前可用于临床试验的最有效的血小板抑制剂之一。